Regulatory T cells in cancer

M Beyer, JL Schultze - Blood, 2006 - ashpublications.org
Blood, 2006ashpublications.org
Increasing evidence supports the existence of elevated numbers of regulatory T cells (Treg
cells) in solid tumors and hematologic malignancies. Whereas the biology of CD4+ CD25+
FOXP3+ Treg cells in murine models seems to be rather straightforward, studies in human
diseases are more difficult to interpret due to expression of CD25 on activated effector T
cells as well as Treg cells. More importantly, early studies in human tumors were mainly
focused on CD4+ CD25+ Treg cells lacking interrogation of more specific markers such as …
Abstract
Increasing evidence supports the existence of elevated numbers of regulatory T cells (Treg cells) in solid tumors and hematologic malignancies. Whereas the biology of CD4+CD25+FOXP3+ Treg cells in murine models seems to be rather straightforward, studies in human diseases are more difficult to interpret due to expression of CD25 on activated effector T cells as well as Treg cells. More importantly, early studies in human tumors were mainly focused on CD4+CD25+ Treg cells lacking interrogation of more specific markers such as FOXP3 expression. Although the increase of Treg cells seems to be a characteristic feature in most tumors, little is known about the molecular and cellular mechanisms responsible for the increase and maintenance of elevated levels of Treg cells in cancer. We will discuss earlier data in the context of recent findings in Treg-cell biology with a particular emphasis on CD4+CD25highFOXP3+ Treg cells in human malignancies.
ashpublications.org